{ "kind": "all", "value": "all", "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations", "filters": { "documentKinds": [], "sourceTypes": [], "orientations": [] }, "total": 319975, "page": 3586, "pageSize": 60, "pageCount": 5333, "rows": [ { "docId": "019de075-c130-77ea-b60f-b21955e0fc8e", "docSlug": "71c1598fd07d494c4a73d86584bdcfa9", "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 34, "slideType": "solution", "function": "present_solution", "notes": "Includes three distinct charts: a dot plot for IC50, a bar chart for selectivity index, and a bar chart for brain penetrance.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/34", "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-34", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c130-77ea-b60f-b21955e0fc8e", "docSlug": "71c1598fd07d494c4a73d86584bdcfa9", "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 35, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/35", "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-35", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c130-77ea-b60f-b21955e0fc8e", "docSlug": "71c1598fd07d494c4a73d86584bdcfa9", "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 36, "slideType": "other", "function": "present_framework", "notes": "The slide uses a cascading hexagonal process flow to illustrate the methodology.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/36", "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-36", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c130-77ea-b60f-b21955e0fc8e", "docSlug": "71c1598fd07d494c4a73d86584bdcfa9", "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 37, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a timeline-style layout to track drug development progress from discovery through clinical phases.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/37", "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-37", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c130-77ea-b60f-b21955e0fc8e", "docSlug": "71c1598fd07d494c4a73d86584bdcfa9", "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 38, "slideType": "solution", "function": "present_solution", "notes": "Includes a molecular structure visualization.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/38", "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-38", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c130-77ea-b60f-b21955e0fc8e", "docSlug": "71c1598fd07d494c4a73d86584bdcfa9", "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 39, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/39", "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-39", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c1ce-7016-922a-ee59c26b52e2", "docSlug": "7a9033616f2f52a3ff84a89721dd4a41", "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 23 slides", "authorId": "nuvectis-pharma", "authorName": "Nuvectis Pharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 1, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": "https://imgproxy.kitesheet.com/yroQK3zbTMBtfO2wQrdZv8Pqayk0kDvxaq8HcWPAma8/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy83YTkwMzM2MTZmMmY1MmEzZmY4NGE4OTcyMWRkNGE0MS9wMDAxLmpwZw", "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c1ce-7016-922a-ee59c26b52e2/1", "deckHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2", "deckAnchorHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2#slide-1", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": "https://imgproxy.kitesheet.com/LLEhaiF1pJcXaTkBO0T2dDNvOdc8kkUJcNl44oNbagc/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy83YTkwMzM2MTZmMmY1MmEzZmY4NGE4OTcyMWRkNGE0MS9wMDAxLnBuZw", "thumbSrc": "https://imgproxy.kitesheet.com/llNVY4iSXGjt50GkzvJ4bUgADBI9TuyMxgP0kCmubWk/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy83YTkwMzM2MTZmMmY1MmEzZmY4NGE4OTcyMWRkNGE0MS9wMDAxLmpwZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/l12qKXf698vnJ2R-WXjM7jy68fliDKfz7h2hZdjBiQk/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy83YTkwMzM2MTZmMmY1MmEzZmY4NGE4OTcyMWRkNGE0MS9wMDAxLnBuZw" }, { "docId": "019de075-c1ce-7016-922a-ee59c26b52e2", "docSlug": "7a9033616f2f52a3ff84a89721dd4a41", "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 23 slides", "authorId": "nuvectis-pharma", "authorName": "Nuvectis Pharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 2, "slideType": "appendix_disclosure", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c1ce-7016-922a-ee59c26b52e2/2", "deckHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2", "deckAnchorHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2#slide-2", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c1ce-7016-922a-ee59c26b52e2", "docSlug": "7a9033616f2f52a3ff84a89721dd4a41", "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 23 slides", "authorId": "nuvectis-pharma", "authorName": "Nuvectis Pharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 3, "slideType": "executive_summary", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c1ce-7016-922a-ee59c26b52e2/3", "deckHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2", "deckAnchorHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2#slide-3", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c1ce-7016-922a-ee59c26b52e2", "docSlug": "7a9033616f2f52a3ff84a89721dd4a41", "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 23 slides", "authorId": "nuvectis-pharma", "authorName": "Nuvectis Pharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 4, "slideType": "team_bio", "function": "other", "notes": "The slide uses a visual association between the three executives and the logos of companies/products they have been associated with.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c1ce-7016-922a-ee59c26b52e2/4", "deckHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2", "deckAnchorHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2#slide-4", "loopMatches": [], "arcBeatMatches": [ { "to": 4, "from": 4, "beatId": "a79d730d-9331-409d-8981-9771d6b05063", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Team", "beatSlug": "sequoia-pitch-team", "evidence": "The document presents information on the team", "position": 4, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c1ce-7016-922a-ee59c26b52e2", "docSlug": "7a9033616f2f52a3ff84a89721dd4a41", "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 23 slides", "authorId": "nuvectis-pharma", "authorName": "Nuvectis Pharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 5, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a timeline-style layout to represent drug development stages.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c1ce-7016-922a-ee59c26b52e2/5", "deckHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2", "deckAnchorHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2#slide-5", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c1ce-7016-922a-ee59c26b52e2", "docSlug": "7a9033616f2f52a3ff84a89721dd4a41", "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 23 slides", "authorId": "nuvectis-pharma", "authorName": "Nuvectis Pharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 6, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c1ce-7016-922a-ee59c26b52e2/6", "deckHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2", "deckAnchorHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2#slide-6", "loopMatches": [ { "to": 22, "from": 6, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "e81cf698-f51d-4b2d-9877-cb9fc692efbb", "evidence": "The document presents the potential benefits of Nuvectis Pharma's pipeline", "position": 0, "objective": "Highlight the cost of inaction in oncology", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 6, "from": 6, "beatId": "16251d29-a6ee-48fa-b0ff-893962d3572b", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Problem", "beatSlug": "sequoia-pitch-problem", "evidence": "The document presents an overview of the problem in oncology", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c1ce-7016-922a-ee59c26b52e2", "docSlug": "7a9033616f2f52a3ff84a89721dd4a41", "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 23 slides", "authorId": "nuvectis-pharma", "authorName": "Nuvectis Pharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 7, "slideType": "key_takeaways", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c1ce-7016-922a-ee59c26b52e2/7", "deckHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2", "deckAnchorHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2#slide-7", "loopMatches": [ { "to": 22, "from": 6, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "e81cf698-f51d-4b2d-9877-cb9fc692efbb", "evidence": "The document presents the potential benefits of Nuvectis Pharma's pipeline", "position": 0, "objective": "Highlight the cost of inaction in oncology", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" }, { "to": 20, "from": 7, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "e770d6a7-7a71-413e-a8f8-c45403042dac", "evidence": "The document presents data on the potential of NXP800 and NXP900", "position": 1, "objective": "Present Nuvectis Pharma's solution as a quick win and big bet", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 20, "from": 7, "beatId": "c1062702-11f0-40ee-8dcf-e049e6911d1a", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents Nuvectis Pharma's solution, including NXP800 and NXP900", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c1ce-7016-922a-ee59c26b52e2", "docSlug": "7a9033616f2f52a3ff84a89721dd4a41", "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 23 slides", "authorId": "nuvectis-pharma", "authorName": "Nuvectis Pharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 8, "slideType": "solution", "function": "present_solution", "notes": "Includes a molecular pathway diagram and a Western blot image as evidence.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c1ce-7016-922a-ee59c26b52e2/8", "deckHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2", "deckAnchorHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2#slide-8", "loopMatches": [ { "to": 22, "from": 6, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "e81cf698-f51d-4b2d-9877-cb9fc692efbb", "evidence": "The document presents the potential benefits of Nuvectis Pharma's pipeline", "position": 0, "objective": "Highlight the cost of inaction in oncology", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" }, { "to": 20, "from": 7, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "e770d6a7-7a71-413e-a8f8-c45403042dac", "evidence": "The document presents data on the potential of NXP800 and NXP900", "position": 1, "objective": "Present Nuvectis Pharma's solution as a quick win and big bet", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 20, "from": 7, "beatId": "c1062702-11f0-40ee-8dcf-e049e6911d1a", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents Nuvectis Pharma's solution, including NXP800 and NXP900", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c1ce-7016-922a-ee59c26b52e2", "docSlug": "7a9033616f2f52a3ff84a89721dd4a41", "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 23 slides", "authorId": "nuvectis-pharma", "authorName": "Nuvectis Pharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 9, "slideType": "traction", "function": "show_traction", "notes": "The slide demonstrates superior tumor volume reduction by NXP800 compared to standard-of-care Cisplatin in both SKOV-3 and TOV-21G models.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c1ce-7016-922a-ee59c26b52e2/9", "deckHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2", "deckAnchorHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2#slide-9", "loopMatches": [ { "to": 22, "from": 6, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "e81cf698-f51d-4b2d-9877-cb9fc692efbb", "evidence": "The document presents the potential benefits of Nuvectis Pharma's pipeline", "position": 0, "objective": "Highlight the cost of inaction in oncology", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" }, { "to": 20, "from": 7, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "e770d6a7-7a71-413e-a8f8-c45403042dac", "evidence": "The document presents data on the potential of NXP800 and NXP900", "position": 1, "objective": "Present Nuvectis Pharma's solution as a quick win and big bet", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 20, "from": 7, "beatId": "c1062702-11f0-40ee-8dcf-e049e6911d1a", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents Nuvectis Pharma's solution, including NXP800 and NXP900", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" }, { "to": 11, "from": 9, "beatId": "2f58055b-6bfe-4c16-99cc-32b143b3c05f", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Traction", "beatSlug": null, "evidence": "The document presents data on the traction of NXP800 and NXP900", "position": 2, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c1ce-7016-922a-ee59c26b52e2", "docSlug": "7a9033616f2f52a3ff84a89721dd4a41", "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 23 slides", "authorId": "nuvectis-pharma", "authorName": "Nuvectis Pharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 10, "slideType": "traction", "function": "show_traction", "notes": "Includes a patient-derived xenograft (PDX) study workflow diagram and a tumor volume growth curve.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c1ce-7016-922a-ee59c26b52e2/10", "deckHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2", "deckAnchorHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2#slide-10", "loopMatches": [ { "to": 22, "from": 6, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "e81cf698-f51d-4b2d-9877-cb9fc692efbb", "evidence": "The document presents the potential benefits of Nuvectis Pharma's pipeline", "position": 0, "objective": "Highlight the cost of inaction in oncology", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" }, { "to": 20, "from": 7, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "e770d6a7-7a71-413e-a8f8-c45403042dac", "evidence": "The document presents data on the potential of NXP800 and NXP900", "position": 1, "objective": "Present Nuvectis Pharma's solution as a quick win and big bet", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 20, "from": 7, "beatId": "c1062702-11f0-40ee-8dcf-e049e6911d1a", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents Nuvectis Pharma's solution, including NXP800 and NXP900", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" }, { "to": 11, "from": 9, "beatId": "2f58055b-6bfe-4c16-99cc-32b143b3c05f", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Traction", "beatSlug": null, "evidence": "The document presents data on the traction of NXP800 and NXP900", "position": 2, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c1ce-7016-922a-ee59c26b52e2", "docSlug": "7a9033616f2f52a3ff84a89721dd4a41", "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 23 slides", "authorId": "nuvectis-pharma", "authorName": "Nuvectis Pharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 11, "slideType": "traction", "function": "show_traction", "notes": "The chart shows tumor volume reduction over 28 days compared to vehicle control.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c1ce-7016-922a-ee59c26b52e2/11", "deckHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2", "deckAnchorHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2#slide-11", "loopMatches": [ { "to": 22, "from": 6, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "e81cf698-f51d-4b2d-9877-cb9fc692efbb", "evidence": "The document presents the potential benefits of Nuvectis Pharma's pipeline", "position": 0, "objective": "Highlight the cost of inaction in oncology", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" }, { "to": 20, "from": 7, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "e770d6a7-7a71-413e-a8f8-c45403042dac", "evidence": "The document presents data on the potential of NXP800 and NXP900", "position": 1, "objective": "Present Nuvectis Pharma's solution as a quick win and big bet", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 20, "from": 7, "beatId": "c1062702-11f0-40ee-8dcf-e049e6911d1a", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents Nuvectis Pharma's solution, including NXP800 and NXP900", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" }, { "to": 11, "from": 9, "beatId": "2f58055b-6bfe-4c16-99cc-32b143b3c05f", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Traction", "beatSlug": null, "evidence": "The document presents data on the traction of NXP800 and NXP900", "position": 2, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c1ce-7016-922a-ee59c26b52e2", "docSlug": "7a9033616f2f52a3ff84a89721dd4a41", "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 23 slides", "authorId": "nuvectis-pharma", "authorName": "Nuvectis Pharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 12, "slideType": "roadmap", "function": "plan_implementation", "notes": "Clinical trial NCT05226507 status update.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c1ce-7016-922a-ee59c26b52e2/12", "deckHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2", "deckAnchorHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2#slide-12", "loopMatches": [ { "to": 22, "from": 6, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "e81cf698-f51d-4b2d-9877-cb9fc692efbb", "evidence": "The document presents the potential benefits of Nuvectis Pharma's pipeline", "position": 0, "objective": "Highlight the cost of inaction in oncology", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" }, { "to": 20, "from": 7, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "e770d6a7-7a71-413e-a8f8-c45403042dac", "evidence": "The document presents data on the potential of NXP800 and NXP900", "position": 1, "objective": "Present Nuvectis Pharma's solution as a quick win and big bet", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 20, "from": 7, "beatId": "c1062702-11f0-40ee-8dcf-e049e6911d1a", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents Nuvectis Pharma's solution, including NXP800 and NXP900", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" }, { "to": 20, "from": 12, "beatId": "8122ef7d-2234-47f6-ba29-f1f7415cb0cc", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Roadmap", "beatSlug": null, "evidence": "The document presents a roadmap for NXP800 and NXP900", "position": 3, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c1ce-7016-922a-ee59c26b52e2", "docSlug": "7a9033616f2f52a3ff84a89721dd4a41", "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 23 slides", "authorId": "nuvectis-pharma", "authorName": "Nuvectis Pharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 13, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c1ce-7016-922a-ee59c26b52e2/13", "deckHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2", "deckAnchorHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2#slide-13", "loopMatches": [ { "to": 22, "from": 6, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "e81cf698-f51d-4b2d-9877-cb9fc692efbb", "evidence": "The document presents the potential benefits of Nuvectis Pharma's pipeline", "position": 0, "objective": "Highlight the cost of inaction in oncology", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" }, { "to": 20, "from": 7, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "e770d6a7-7a71-413e-a8f8-c45403042dac", "evidence": "The document presents data on the potential of NXP800 and NXP900", "position": 1, "objective": "Present Nuvectis Pharma's solution as a quick win and big bet", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 20, "from": 7, "beatId": "c1062702-11f0-40ee-8dcf-e049e6911d1a", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents Nuvectis Pharma's solution, including NXP800 and NXP900", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" }, { "to": 20, "from": 12, "beatId": "8122ef7d-2234-47f6-ba29-f1f7415cb0cc", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Roadmap", "beatSlug": null, "evidence": "The document presents a roadmap for NXP800 and NXP900", "position": 3, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c1ce-7016-922a-ee59c26b52e2", "docSlug": "7a9033616f2f52a3ff84a89721dd4a41", "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 23 slides", "authorId": "nuvectis-pharma", "authorName": "Nuvectis Pharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 14, "slideType": "key_takeaways", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c1ce-7016-922a-ee59c26b52e2/14", "deckHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2", "deckAnchorHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2#slide-14", "loopMatches": [ { "to": 22, "from": 6, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "e81cf698-f51d-4b2d-9877-cb9fc692efbb", "evidence": "The document presents the potential benefits of Nuvectis Pharma's pipeline", "position": 0, "objective": "Highlight the cost of inaction in oncology", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" }, { "to": 20, "from": 7, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "e770d6a7-7a71-413e-a8f8-c45403042dac", "evidence": "The document presents data on the potential of NXP800 and NXP900", "position": 1, "objective": "Present Nuvectis Pharma's solution as a quick win and big bet", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 20, "from": 7, "beatId": "c1062702-11f0-40ee-8dcf-e049e6911d1a", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents Nuvectis Pharma's solution, including NXP800 and NXP900", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" }, { "to": 20, "from": 12, "beatId": "8122ef7d-2234-47f6-ba29-f1f7415cb0cc", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Roadmap", "beatSlug": null, "evidence": "The document presents a roadmap for NXP800 and NXP900", "position": 3, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c1ce-7016-922a-ee59c26b52e2", "docSlug": "7a9033616f2f52a3ff84a89721dd4a41", "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 23 slides", "authorId": "nuvectis-pharma", "authorName": "Nuvectis Pharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 15, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The visualization is a standard kinome tree map used in pharmaceutical research to demonstrate drug selectivity.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c1ce-7016-922a-ee59c26b52e2/15", "deckHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2", "deckAnchorHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2#slide-15", "loopMatches": [ { "to": 22, "from": 6, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "e81cf698-f51d-4b2d-9877-cb9fc692efbb", "evidence": "The document presents the potential benefits of Nuvectis Pharma's pipeline", "position": 0, "objective": "Highlight the cost of inaction in oncology", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" }, { "to": 20, "from": 7, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "e770d6a7-7a71-413e-a8f8-c45403042dac", "evidence": "The document presents data on the potential of NXP800 and NXP900", "position": 1, "objective": "Present Nuvectis Pharma's solution as a quick win and big bet", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 20, "from": 7, "beatId": "c1062702-11f0-40ee-8dcf-e049e6911d1a", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents Nuvectis Pharma's solution, including NXP800 and NXP900", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" }, { "to": 20, "from": 12, "beatId": "8122ef7d-2234-47f6-ba29-f1f7415cb0cc", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Roadmap", "beatSlug": null, "evidence": "The document presents a roadmap for NXP800 and NXP900", "position": 3, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c1ce-7016-922a-ee59c26b52e2", "docSlug": "7a9033616f2f52a3ff84a89721dd4a41", "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 23 slides", "authorId": "nuvectis-pharma", "authorName": "Nuvectis Pharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 16, "slideType": "solution", "function": "present_solution", "notes": "Uses a structural biology diagram to illustrate mechanism of action.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c1ce-7016-922a-ee59c26b52e2/16", "deckHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2", "deckAnchorHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2#slide-16", "loopMatches": [ { "to": 22, "from": 6, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "e81cf698-f51d-4b2d-9877-cb9fc692efbb", "evidence": "The document presents the potential benefits of Nuvectis Pharma's pipeline", "position": 0, "objective": "Highlight the cost of inaction in oncology", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" }, { "to": 20, "from": 7, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "e770d6a7-7a71-413e-a8f8-c45403042dac", "evidence": "The document presents data on the potential of NXP800 and NXP900", "position": 1, "objective": "Present Nuvectis Pharma's solution as a quick win and big bet", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 20, "from": 7, "beatId": "c1062702-11f0-40ee-8dcf-e049e6911d1a", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents Nuvectis Pharma's solution, including NXP800 and NXP900", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" }, { "to": 20, "from": 12, "beatId": "8122ef7d-2234-47f6-ba29-f1f7415cb0cc", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Roadmap", "beatSlug": null, "evidence": "The document presents a roadmap for NXP800 and NXP900", "position": 3, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c1ce-7016-922a-ee59c26b52e2", "docSlug": "7a9033616f2f52a3ff84a89721dd4a41", "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 23 slides", "authorId": "nuvectis-pharma", "authorName": "Nuvectis Pharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 17, "slideType": "solution", "function": "present_solution", "notes": "Includes a biological pathway diagram, microscopy images, and an IC50 dose-response curve.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c1ce-7016-922a-ee59c26b52e2/17", "deckHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2", "deckAnchorHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2#slide-17", "loopMatches": [ { "to": 22, "from": 6, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "e81cf698-f51d-4b2d-9877-cb9fc692efbb", "evidence": "The document presents the potential benefits of Nuvectis Pharma's pipeline", "position": 0, "objective": "Highlight the cost of inaction in oncology", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" }, { "to": 20, "from": 7, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "e770d6a7-7a71-413e-a8f8-c45403042dac", "evidence": "The document presents data on the potential of NXP800 and NXP900", "position": 1, "objective": "Present Nuvectis Pharma's solution as a quick win and big bet", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 20, "from": 7, "beatId": "c1062702-11f0-40ee-8dcf-e049e6911d1a", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents Nuvectis Pharma's solution, including NXP800 and NXP900", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" }, { "to": 20, "from": 12, "beatId": "8122ef7d-2234-47f6-ba29-f1f7415cb0cc", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Roadmap", "beatSlug": null, "evidence": "The document presents a roadmap for NXP800 and NXP900", "position": 3, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c1ce-7016-922a-ee59c26b52e2", "docSlug": "7a9033616f2f52a3ff84a89721dd4a41", "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 23 slides", "authorId": "nuvectis-pharma", "authorName": "Nuvectis Pharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 18, "slideType": "traction", "function": "show_traction", "notes": "The charts demonstrate efficacy in specific cell lines (KYSE70 and Cal27) with known genetic alterations.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c1ce-7016-922a-ee59c26b52e2/18", "deckHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2", "deckAnchorHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2#slide-18", "loopMatches": [ { "to": 22, "from": 6, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "e81cf698-f51d-4b2d-9877-cb9fc692efbb", "evidence": "The document presents the potential benefits of Nuvectis Pharma's pipeline", "position": 0, "objective": "Highlight the cost of inaction in oncology", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" }, { "to": 20, "from": 7, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "e770d6a7-7a71-413e-a8f8-c45403042dac", "evidence": "The document presents data on the potential of NXP800 and NXP900", "position": 1, "objective": "Present Nuvectis Pharma's solution as a quick win and big bet", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 20, "from": 7, "beatId": "c1062702-11f0-40ee-8dcf-e049e6911d1a", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents Nuvectis Pharma's solution, including NXP800 and NXP900", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" }, { "to": 20, "from": 12, "beatId": "8122ef7d-2234-47f6-ba29-f1f7415cb0cc", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Roadmap", "beatSlug": null, "evidence": "The document presents a roadmap for NXP800 and NXP900", "position": 3, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c1ce-7016-922a-ee59c26b52e2", "docSlug": "7a9033616f2f52a3ff84a89721dd4a41", "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 23 slides", "authorId": "nuvectis-pharma", "authorName": "Nuvectis Pharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 19, "slideType": "solution", "function": "present_solution", "notes": "Includes two distinct experimental setups: cell proliferation assays and mouse tumor growth models.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c1ce-7016-922a-ee59c26b52e2/19", "deckHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2", "deckAnchorHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2#slide-19", "loopMatches": [ { "to": 22, "from": 6, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "e81cf698-f51d-4b2d-9877-cb9fc692efbb", "evidence": "The document presents the potential benefits of Nuvectis Pharma's pipeline", "position": 0, "objective": "Highlight the cost of inaction in oncology", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" }, { "to": 20, "from": 7, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "e770d6a7-7a71-413e-a8f8-c45403042dac", "evidence": "The document presents data on the potential of NXP800 and NXP900", "position": 1, "objective": "Present Nuvectis Pharma's solution as a quick win and big bet", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 20, "from": 7, "beatId": "c1062702-11f0-40ee-8dcf-e049e6911d1a", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents Nuvectis Pharma's solution, including NXP800 and NXP900", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" }, { "to": 20, "from": 12, "beatId": "8122ef7d-2234-47f6-ba29-f1f7415cb0cc", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Roadmap", "beatSlug": null, "evidence": "The document presents a roadmap for NXP800 and NXP900", "position": 3, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c1ce-7016-922a-ee59c26b52e2", "docSlug": "7a9033616f2f52a3ff84a89721dd4a41", "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 23 slides", "authorId": "nuvectis-pharma", "authorName": "Nuvectis Pharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 20, "slideType": "roadmap", "function": "plan_implementation", "notes": "Clinical trial identifier NCT05873686 is provided.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c1ce-7016-922a-ee59c26b52e2/20", "deckHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2", "deckAnchorHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2#slide-20", "loopMatches": [ { "to": 22, "from": 6, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "e81cf698-f51d-4b2d-9877-cb9fc692efbb", "evidence": "The document presents the potential benefits of Nuvectis Pharma's pipeline", "position": 0, "objective": "Highlight the cost of inaction in oncology", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" }, { "to": 20, "from": 7, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "e770d6a7-7a71-413e-a8f8-c45403042dac", "evidence": "The document presents data on the potential of NXP800 and NXP900", "position": 1, "objective": "Present Nuvectis Pharma's solution as a quick win and big bet", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 20, "from": 7, "beatId": "c1062702-11f0-40ee-8dcf-e049e6911d1a", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents Nuvectis Pharma's solution, including NXP800 and NXP900", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" }, { "to": 20, "from": 12, "beatId": "8122ef7d-2234-47f6-ba29-f1f7415cb0cc", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Roadmap", "beatSlug": null, "evidence": "The document presents a roadmap for NXP800 and NXP900", "position": 3, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c1ce-7016-922a-ee59c26b52e2", "docSlug": "7a9033616f2f52a3ff84a89721dd4a41", "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 23 slides", "authorId": "nuvectis-pharma", "authorName": "Nuvectis Pharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 21, "slideType": "appendix_data", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c1ce-7016-922a-ee59c26b52e2/21", "deckHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2", "deckAnchorHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2#slide-21", "loopMatches": [ { "to": 22, "from": 6, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "e81cf698-f51d-4b2d-9877-cb9fc692efbb", "evidence": "The document presents the potential benefits of Nuvectis Pharma's pipeline", "position": 0, "objective": "Highlight the cost of inaction in oncology", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c1ce-7016-922a-ee59c26b52e2", "docSlug": "7a9033616f2f52a3ff84a89721dd4a41", "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 23 slides", "authorId": "nuvectis-pharma", "authorName": "Nuvectis Pharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 22, "slideType": "executive_summary", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c1ce-7016-922a-ee59c26b52e2/22", "deckHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2", "deckAnchorHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2#slide-22", "loopMatches": [ { "to": 22, "from": 6, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "e81cf698-f51d-4b2d-9877-cb9fc692efbb", "evidence": "The document presents the potential benefits of Nuvectis Pharma's pipeline", "position": 0, "objective": "Highlight the cost of inaction in oncology", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c1ce-7016-922a-ee59c26b52e2", "docSlug": "7a9033616f2f52a3ff84a89721dd4a41", "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 23 slides", "authorId": "nuvectis-pharma", "authorName": "Nuvectis Pharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 23, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c1ce-7016-922a-ee59c26b52e2/23", "deckHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2", "deckAnchorHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2#slide-23", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c271-76b0-93dc-83fc11d89a0a", "docSlug": "02b6062de9eaa354c342bde35d366a5d", "documentTitle": "Nuwellis | Investor Presentation Deck | 29 slides", "authorId": "nuwellis", "authorName": "Nuwellis", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 1, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": "https://imgproxy.kitesheet.com/xfgi7dBnp4oTxaN5nppzh2IfNOx2FuBPFjeOOdjX6R4/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8wMmI2MDYyZGU5ZWFhMzU0YzM0MmJkZTM1ZDM2NmE1ZC9wMDAxLmpwZw", "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c271-76b0-93dc-83fc11d89a0a/1", "deckHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a", "deckAnchorHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a#slide-1", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": "https://imgproxy.kitesheet.com/T2nM3lJBij7vGzjFNefDFstm3qc85EQppxLQ1DusOVo/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8wMmI2MDYyZGU5ZWFhMzU0YzM0MmJkZTM1ZDM2NmE1ZC9wMDAxLnBuZw", "thumbSrc": "https://imgproxy.kitesheet.com/IUMGQzUvvnaxF8YE-I3NgF1qI8Xfgx3jR28pI3HUDG0/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8wMmI2MDYyZGU5ZWFhMzU0YzM0MmJkZTM1ZDM2NmE1ZC9wMDAxLmpwZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/Pf7sL01F5DLa_zqUZqAFzAUzPLRkrbIdjAf4GBSGl-w/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8wMmI2MDYyZGU5ZWFhMzU0YzM0MmJkZTM1ZDM2NmE1ZC9wMDAxLnBuZw" }, { "docId": "019de075-c271-76b0-93dc-83fc11d89a0a", "docSlug": "02b6062de9eaa354c342bde35d366a5d", "documentTitle": "Nuwellis | Investor Presentation Deck | 29 slides", "authorId": "nuwellis", "authorName": "Nuwellis", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 2, "slideType": "disclaimer", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c271-76b0-93dc-83fc11d89a0a/2", "deckHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a", "deckAnchorHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a#slide-2", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c271-76b0-93dc-83fc11d89a0a", "docSlug": "02b6062de9eaa354c342bde35d366a5d", "documentTitle": "Nuwellis | Investor Presentation Deck | 29 slides", "authorId": "nuwellis", "authorName": "Nuwellis", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 3, "slideType": "mission", "function": "inspire_vision", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c271-76b0-93dc-83fc11d89a0a/3", "deckHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a", "deckAnchorHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a#slide-3", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c271-76b0-93dc-83fc11d89a0a", "docSlug": "02b6062de9eaa354c342bde35d366a5d", "documentTitle": "Nuwellis | Investor Presentation Deck | 29 slides", "authorId": "nuwellis", "authorName": "Nuwellis", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 4, "slideType": "executive_summary", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c271-76b0-93dc-83fc11d89a0a/4", "deckHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a", "deckAnchorHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a#slide-4", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c271-76b0-93dc-83fc11d89a0a", "docSlug": "02b6062de9eaa354c342bde35d366a5d", "documentTitle": "Nuwellis | Investor Presentation Deck | 29 slides", "authorId": "nuwellis", "authorName": "Nuwellis", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 5, "slideType": "team_bio", "function": "summarize", "notes": "Includes headshots and titles for 8 executives.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c271-76b0-93dc-83fc11d89a0a/5", "deckHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a", "deckAnchorHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a#slide-5", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c271-76b0-93dc-83fc11d89a0a", "docSlug": "02b6062de9eaa354c342bde35d366a5d", "documentTitle": "Nuwellis | Investor Presentation Deck | 29 slides", "authorId": "nuwellis", "authorName": "Nuwellis", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 6, "slideType": "problem_statement", "function": "frame_problem", "notes": "The slide uses a numbered list format to categorize the problem into four distinct areas: clinical outcomes, cost/length of stay, reimbursement losses, and readmission penalties.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c271-76b0-93dc-83fc11d89a0a/6", "deckHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a", "deckAnchorHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a#slide-6", "loopMatches": [], "arcBeatMatches": [ { "to": 8, "from": 6, "beatId": "7757341f-8a18-4e2c-8526-20927a4ea2b6", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Problem", "beatSlug": "problem-agitate-solution-problem-identify-pain", "evidence": "Slides 6-8 identify the problem of fluid overload and its limitations", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c271-76b0-93dc-83fc11d89a0a", "docSlug": "02b6062de9eaa354c342bde35d366a5d", "documentTitle": "Nuwellis | Investor Presentation Deck | 29 slides", "authorId": "nuwellis", "authorName": "Nuwellis", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 7, "slideType": "problem_statement", "function": "frame_problem", "notes": "Includes medical citations for each claim.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c271-76b0-93dc-83fc11d89a0a/7", "deckHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a", "deckAnchorHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a#slide-7", "loopMatches": [], "arcBeatMatches": [ { "to": 8, "from": 6, "beatId": "7757341f-8a18-4e2c-8526-20927a4ea2b6", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Problem", "beatSlug": "problem-agitate-solution-problem-identify-pain", "evidence": "Slides 6-8 identify the problem of fluid overload and its limitations", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c271-76b0-93dc-83fc11d89a0a", "docSlug": "02b6062de9eaa354c342bde35d366a5d", "documentTitle": "Nuwellis | Investor Presentation Deck | 29 slides", "authorId": "nuwellis", "authorName": "Nuwellis", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 8, "slideType": "problem_statement", "function": "frame_problem", "notes": "Includes medical citations at the bottom.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c271-76b0-93dc-83fc11d89a0a/8", "deckHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a", "deckAnchorHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a#slide-8", "loopMatches": [], "arcBeatMatches": [ { "to": 8, "from": 6, "beatId": "7757341f-8a18-4e2c-8526-20927a4ea2b6", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Problem", "beatSlug": "problem-agitate-solution-problem-identify-pain", "evidence": "Slides 6-8 identify the problem of fluid overload and its limitations", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c271-76b0-93dc-83fc11d89a0a", "docSlug": "02b6062de9eaa354c342bde35d366a5d", "documentTitle": "Nuwellis | Investor Presentation Deck | 29 slides", "authorId": "nuwellis", "authorName": "Nuwellis", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 9, "slideType": "solution", "function": "present_solution", "notes": "Includes a list of clinical citations at the bottom.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c271-76b0-93dc-83fc11d89a0a/9", "deckHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a", "deckAnchorHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a#slide-9", "loopMatches": [], "arcBeatMatches": [ { "to": 9, "from": 9, "beatId": "637f86ca-8791-4f60-8c7f-ea9f329ec31a", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "Slide 9 presents the solution: Aquadex ultrafiltration device", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c271-76b0-93dc-83fc11d89a0a", "docSlug": "02b6062de9eaa354c342bde35d366a5d", "documentTitle": "Nuwellis | Investor Presentation Deck | 29 slides", "authorId": "nuwellis", "authorName": "Nuwellis", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 10, "slideType": "solution", "function": "present_solution", "notes": "Uses a numbered process flow diagram to explain medical device operation.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c271-76b0-93dc-83fc11d89a0a/10", "deckHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a", "deckAnchorHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a#slide-10", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c271-76b0-93dc-83fc11d89a0a", "docSlug": "02b6062de9eaa354c342bde35d366a5d", "documentTitle": "Nuwellis | Investor Presentation Deck | 29 slides", "authorId": "nuwellis", "authorName": "Nuwellis", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 11, "slideType": "traction", "function": "show_traction", "notes": "Includes citation references and a 'Newly published' callout for the Abington Hospital study.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c271-76b0-93dc-83fc11d89a0a/11", "deckHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a", "deckAnchorHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a#slide-11", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c271-76b0-93dc-83fc11d89a0a", "docSlug": "02b6062de9eaa354c342bde35d366a5d", "documentTitle": "Nuwellis | Investor Presentation Deck | 29 slides", "authorId": "nuwellis", "authorName": "Nuwellis", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 12, "slideType": "traction", "function": "show_traction", "notes": "Includes logos for UChicago Medicine and Lenox Hill Hospital/Northwell Health.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c271-76b0-93dc-83fc11d89a0a/12", "deckHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a", "deckAnchorHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a#slide-12", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c271-76b0-93dc-83fc11d89a0a", "docSlug": "02b6062de9eaa354c342bde35d366a5d", "documentTitle": "Nuwellis | Investor Presentation Deck | 29 slides", "authorId": "nuwellis", "authorName": "Nuwellis", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 13, "slideType": "why_now", "function": "argue_timing", "notes": "The slide uses a split-layout to contrast the problem (diuretic resistance) with the solution (ultrafiltration) supported by clinical evidence.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c271-76b0-93dc-83fc11d89a0a/13", "deckHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a", "deckAnchorHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a#slide-13", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c271-76b0-93dc-83fc11d89a0a", "docSlug": "02b6062de9eaa354c342bde35d366a5d", "documentTitle": "Nuwellis | Investor Presentation Deck | 29 slides", "authorId": "nuwellis", "authorName": "Nuwellis", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 14, "slideType": "traction", "function": "show_traction", "notes": "Slide features a press release excerpt detailing the partnership.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c271-76b0-93dc-83fc11d89a0a/14", "deckHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a", "deckAnchorHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a#slide-14", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c271-76b0-93dc-83fc11d89a0a", "docSlug": "02b6062de9eaa354c342bde35d366a5d", "documentTitle": "Nuwellis | Investor Presentation Deck | 29 slides", "authorId": "nuwellis", "authorName": "Nuwellis", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 15, "slideType": "market_sizing", "function": "size_opportunity", "notes": "The slide uses a matrix-like layout to categorize market segments by time horizon.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c271-76b0-93dc-83fc11d89a0a/15", "deckHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a", "deckAnchorHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a#slide-15", "loopMatches": [], "arcBeatMatches": [ { "to": 15, "from": 15, "beatId": "20c6404e-b72f-4a99-be8b-32b51a523bad", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Market Size", "beatSlug": "sequoia-pitch-market-size", "evidence": "Slide 15 discusses market sizing and growth opportunities", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c271-76b0-93dc-83fc11d89a0a", "docSlug": "02b6062de9eaa354c342bde35d366a5d", "documentTitle": "Nuwellis | Investor Presentation Deck | 29 slides", "authorId": "nuwellis", "authorName": "Nuwellis", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 16, "slideType": "problem_statement", "function": "frame_problem", "notes": "The chart is a Kaplan-Meier survival curve showing the impact of fluid overload on patient outcomes.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c271-76b0-93dc-83fc11d89a0a/16", "deckHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a", "deckAnchorHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a#slide-16", "loopMatches": [ { "to": 16, "from": 16, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "c48148be-5a19-4923-acf8-61fd45bef02c", "evidence": "Slide 16 associates fluid overload with greater mortality", "position": 0, "objective": "Highlight the cost of inaction for fluid overload patients", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 16, "from": 16, "beatId": "52b540ac-05dc-4e13-9733-316c934552c1", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "Slide 16 highlights the association of fluid overload with greater mortality in post-cardiac surgery patients", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c271-76b0-93dc-83fc11d89a0a", "docSlug": "02b6062de9eaa354c342bde35d366a5d", "documentTitle": "Nuwellis | Investor Presentation Deck | 29 slides", "authorId": "nuwellis", "authorName": "Nuwellis", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 17, "slideType": "traction", "function": "show_traction", "notes": "Includes a testimonial from a NICU nurse practitioner.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c271-76b0-93dc-83fc11d89a0a/17", "deckHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a", "deckAnchorHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a#slide-17", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c271-76b0-93dc-83fc11d89a0a", "docSlug": "02b6062de9eaa354c342bde35d366a5d", "documentTitle": "Nuwellis | Investor Presentation Deck | 29 slides", "authorId": "nuwellis", "authorName": "Nuwellis", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 18, "slideType": "traction", "function": "show_traction", "notes": "The slide highlights high survival rates, particularly in the <10kg group which traditionally receives no therapy.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c271-76b0-93dc-83fc11d89a0a/18", "deckHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a", "deckAnchorHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a#slide-18", "loopMatches": [ { "to": 18, "from": 18, "name": "Jobs To Be Done", "slug": "53-jobs-to-be-done", "bestFor": "Product innovation, market entry, competitive positioning", "matchId": "e7acb6c0-dba4-488c-94ac-869c8baca034", "evidence": "Slide 18 discusses pediatric patients with high mortality risk", "position": 1, "objective": "Emphasize the need for a solution in pediatric patients", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "confidence": 0.6, "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c271-76b0-93dc-83fc11d89a0a", "docSlug": "02b6062de9eaa354c342bde35d366a5d", "documentTitle": "Nuwellis | Investor Presentation Deck | 29 slides", "authorId": "nuwellis", "authorName": "Nuwellis", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 19, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a split-pane layout: left side for problem/market context, right side for product solution.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c271-76b0-93dc-83fc11d89a0a/19", "deckHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a", "deckAnchorHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a#slide-19", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c271-76b0-93dc-83fc11d89a0a", "docSlug": "02b6062de9eaa354c342bde35d366a5d", "documentTitle": "Nuwellis | Investor Presentation Deck | 29 slides", "authorId": "nuwellis", "authorName": "Nuwellis", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 20, "slideType": "market_sizing", "function": "size_opportunity", "notes": "The slide uses a funnel-like visual to aggregate market segments into a total TAM.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c271-76b0-93dc-83fc11d89a0a/20", "deckHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a", "deckAnchorHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a#slide-20", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c271-76b0-93dc-83fc11d89a0a", "docSlug": "02b6062de9eaa354c342bde35d366a5d", "documentTitle": "Nuwellis | Investor Presentation Deck | 29 slides", "authorId": "nuwellis", "authorName": "Nuwellis", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 21, "slideType": "unfair_advantage", "function": "other", "notes": "The slide uses a process-like diagram to categorize the IP coverage across five key technology domains.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c271-76b0-93dc-83fc11d89a0a/21", "deckHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a", "deckAnchorHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a#slide-21", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c271-76b0-93dc-83fc11d89a0a", "docSlug": "02b6062de9eaa354c342bde35d366a5d", "documentTitle": "Nuwellis | Investor Presentation Deck | 29 slides", "authorId": "nuwellis", "authorName": "Nuwellis", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 22, "slideType": "timeline", "function": "plan_implementation", "notes": "The slide uses a color-coded legend to distinguish between clinical, commercial, product, and partnership milestones.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c271-76b0-93dc-83fc11d89a0a/22", "deckHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a", "deckAnchorHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a#slide-22", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c271-76b0-93dc-83fc11d89a0a", "docSlug": "02b6062de9eaa354c342bde35d366a5d", "documentTitle": "Nuwellis | Investor Presentation Deck | 29 slides", "authorId": "nuwellis", "authorName": "Nuwellis", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 23, "slideType": "traction", "function": "show_traction", "notes": "Includes a 'Growth Agenda' list and financial status indicators (cash/debt).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c271-76b0-93dc-83fc11d89a0a/23", "deckHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a", "deckAnchorHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a#slide-23", "loopMatches": [], "arcBeatMatches": [ { "to": 23, "from": 23, "beatId": "47a8d387-1d22-42b0-aca0-275e890dbb7d", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Financials", "beatSlug": "sequoia-pitch-financials", "evidence": "Slide 23 provides a financial snapshot", "position": 4, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c271-76b0-93dc-83fc11d89a0a", "docSlug": "02b6062de9eaa354c342bde35d366a5d", "documentTitle": "Nuwellis | Investor Presentation Deck | 29 slides", "authorId": "nuwellis", "authorName": "Nuwellis", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 24, "slideType": "executive_summary", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c271-76b0-93dc-83fc11d89a0a/24", "deckHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a", "deckAnchorHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a#slide-24", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c271-76b0-93dc-83fc11d89a0a", "docSlug": "02b6062de9eaa354c342bde35d366a5d", "documentTitle": "Nuwellis | Investor Presentation Deck | 29 slides", "authorId": "nuwellis", "authorName": "Nuwellis", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 25, "slideType": "mission", "function": "inspire_vision", "notes": "This is a mission statement slide.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c271-76b0-93dc-83fc11d89a0a/25", "deckHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a", "deckAnchorHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a#slide-25", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c271-76b0-93dc-83fc11d89a0a", "docSlug": "02b6062de9eaa354c342bde35d366a5d", "documentTitle": "Nuwellis | Investor Presentation Deck | 29 slides", "authorId": "nuwellis", "authorName": "Nuwellis", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 26, "slideType": "appendix", "function": "appendix", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c271-76b0-93dc-83fc11d89a0a/26", "deckHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a", "deckAnchorHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a#slide-26", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c271-76b0-93dc-83fc11d89a0a", "docSlug": "02b6062de9eaa354c342bde35d366a5d", "documentTitle": "Nuwellis | Investor Presentation Deck | 29 slides", "authorId": "nuwellis", "authorName": "Nuwellis", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 27, "slideType": "other", "function": "establish_context", "notes": "The slide uses a bulleted list to represent a timeline of corporate events.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c271-76b0-93dc-83fc11d89a0a/27", "deckHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a", "deckAnchorHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a#slide-27", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c271-76b0-93dc-83fc11d89a0a", "docSlug": "02b6062de9eaa354c342bde35d366a5d", "documentTitle": "Nuwellis | Investor Presentation Deck | 29 slides", "authorId": "nuwellis", "authorName": "Nuwellis", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 28, "slideType": "traction", "function": "show_traction", "notes": "Includes a callout box at the bottom summarizing strategic goals.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c271-76b0-93dc-83fc11d89a0a/28", "deckHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a", "deckAnchorHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a#slide-28", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c271-76b0-93dc-83fc11d89a0a", "docSlug": "02b6062de9eaa354c342bde35d366a5d", "documentTitle": "Nuwellis | Investor Presentation Deck | 29 slides", "authorId": "nuwellis", "authorName": "Nuwellis", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 29, "slideType": "appendix_data", "function": "analyze_data", "notes": "This slide serves as a technical appendix for market sizing claims made elsewhere in the deck.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c271-76b0-93dc-83fc11d89a0a/29", "deckHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a", "deckAnchorHref": "/decks/019de075-c271-76b0-93dc-83fc11d89a0a#slide-29", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-c33c-777c-b750-195774ea344d", "docSlug": "8d884b07f6bde07d27ba40601badfcaa", "documentTitle": "Old Second Bancorp | Investor Conference Presentation Deck | 21 slides", "authorId": "old-second-bancorp", "authorName": "Old Second Bancorp", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 1, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": "https://imgproxy.kitesheet.com/oLVnp4OCL6s5QTjlJiIF4EIUTMKhhwZowRYlQO6cdXs/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy84ZDg4NGIwN2Y2YmRlMDdkMjdiYTQwNjAxYmFkZmNhYS9wMDAxLmpwZw", "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c33c-777c-b750-195774ea344d/1", "deckHref": "/decks/019de075-c33c-777c-b750-195774ea344d", "deckAnchorHref": "/decks/019de075-c33c-777c-b750-195774ea344d#slide-1", "loopMatches": [], "arcBeatMatches": [ { "to": 6, "from": 1, "beatId": "77646dbd-47dc-4c96-9a23-98fa3f326724", "arcName": "The Sparkline", "arcSlug": "sparkline", "beatName": "What Is", "beatSlug": "sparkline-what-is-1", "evidence": "The initial slides provide an overview of the bank's current situation and financial performance.", "position": 0, "confidence": 0.8, "parentBeatName": "Setup", "parentBeatSlug": "setup" } ], "imagePathAlt": "https://imgproxy.kitesheet.com/UyFg3GfkSHum1PWRF4N1Hfe9gk1Tvf5EgR0yh6MBFzY/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy84ZDg4NGIwN2Y2YmRlMDdkMjdiYTQwNjAxYmFkZmNhYS9wMDAxLnBuZw", "thumbSrc": "https://imgproxy.kitesheet.com/j8Y7-DslrAM8chGhcFtjzqpu6Nn3PCPAsGjV9FdHuWI/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy84ZDg4NGIwN2Y2YmRlMDdkMjdiYTQwNjAxYmFkZmNhYS9wMDAxLmpwZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/ZuSJIoXuwLSutnW0jIkvESlC9J5WRGCy6P-JM199mWM/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy84ZDg4NGIwN2Y2YmRlMDdkMjdiYTQwNjAxYmFkZmNhYS9wMDAxLnBuZw" }, { "docId": "019de075-c33c-777c-b750-195774ea344d", "docSlug": "8d884b07f6bde07d27ba40601badfcaa", "documentTitle": "Old Second Bancorp | Investor Conference Presentation Deck | 21 slides", "authorId": "old-second-bancorp", "authorName": "Old Second Bancorp", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 2, "slideType": "appendix_disclosure", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-c33c-777c-b750-195774ea344d/2", "deckHref": "/decks/019de075-c33c-777c-b750-195774ea344d", "deckAnchorHref": "/decks/019de075-c33c-777c-b750-195774ea344d#slide-2", "loopMatches": [], "arcBeatMatches": [ { "to": 6, "from": 1, "beatId": "77646dbd-47dc-4c96-9a23-98fa3f326724", "arcName": "The Sparkline", "arcSlug": "sparkline", "beatName": "What Is", "beatSlug": "sparkline-what-is-1", "evidence": "The initial slides provide an overview of the bank's current situation and financial performance.", "position": 0, "confidence": 0.8, "parentBeatName": "Setup", "parentBeatSlug": "setup" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true } ] }